Abstract. MicroRNAs (miRNAs/miRs) are crucial molecules that act as tumor suppressor genes or oncogenes in human cancer progression. The dysregulation of miRNA expression has been detected in liver cancer. The present study aimed to explore the molecular mechanisms by which miR-214 affects liver cancer cell proliferation. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of miR-214 in liver cancer cell lines and hepatocellular carcinoma (HCC) tissues. A luciferase reporter assay was performed to determine whether Wnt3a is a target gene of miR-214. Cell Counting kit-8 and cell cycle analysis were used to explore the effects of miR-214 on liver cancer cell proliferation. Immunohistochemistry was used to detect protein expression levels. Wnt3a knockdown was used to determine the function of Wnt3a in liver cancer cell proliferation. The results demonstrated that the expression levels of human miR-214 were reduced in HCC tissues and liver cancer cell lines compared with in control tissues and cells. Overexpression of miR-214 and Wnt3a silencing each inhibited liver cancer cell growth. Conversely, inhibition of miR-214 promoted liver cancer cell growth. The present study indicated that miR-214 acts as a tumor suppressor and may be considered a promising therapeutic target for the treatment of liver cancer.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common types of malignancy worldwide, with ~630,000 new cases reported each year (1). HCC development is a complex process that is associated with numerous risk factors, including several known environmental factors, hepatitis, and alcohol and tobacco consumption (2,3). There is increasing evidence supporting the role of genetic factors in HCC risk (4). The lack of novel therapeutic strategies for the treatment of HCC emphasizes the need to determine the molecular mechanisms underlying liver cancer development. MicroRNAs (miRNAs/miRs) are a class of endogenous, non-coding RNAs 18-22 nucleotides in length, which are crucial for gene expression regulation (5). In the present study, differential miRNA expression between tumor tissues and normal tissues was identified to be associated with cancer progression via target gene regulation. More than half of miRNAs are located in tumor-associated genomic regions or fragile sites (6), and miRNAs may be classified as tumor suppressors or oncogenes based on their modulation of oncogenic and tumor suppressor pathways (7). Numerous miRNAs are involved in liver cancer development, proliferation, apoptosis and differentiation (8). For example, miR-150-5p inhibits hepatoma cell migration and invasion by targeting matrix metalloproteinase 14 (9) and miR-486-5p suppresses tumor growth in HCC by targeting phosphatidylinositol 3-kinase regulatory subunit α (10).

The present study demonstrated that miR-214 expression is lower in HCC tissues and liver cancer cell lines compared with in matched normal tissues and the HL-7702 cell line,
indicating its role as a tumor suppressor in liver cancer. In addition, Wnt3a was confirmed as a target gene of miR-214. Using immunohistochemistry, the present study indicated that the expression of Wnt3a was higher in HCC tissues compared with normal tissues. In addition, the function of miR-214 in liver cancer cell proliferation was investigated, and over-expression of miR-214 and Wnt3a silencing arrested the liver cancer cell cycle at G1 phase. These results demonstrated that miR-214 may suppress the growth of liver cancer cells by targeting Wnt3a.

Materials and methods

Human tissue samples and cell lines. The SMMC-7721, HepG2 and Hep3B liver cancer cell lines, and the HL-7702 normal liver cell line were provided by the Key University, Ministry of Education (Xi'an, China). These cells were cultured in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Inc.) at 37°C in a humidified chamber containing 5% CO2. Tumor tissues and matched normal tissues were obtained from 24 HCC patients (19 males, 5 females; age, 21-72 years). Patients were enrolled between September 2011 and January 2013 at the First Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China). All patients provided written informed consent. The present study was approved by the Medical Ethical Committee of the College of Medicine, Xi'an Jiaotong University (Xi'an, China).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) from the cells or tissues according to the manufacturer's protocol. cDNA synthesis was performed using the Prime-Script RT Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. qPCR was performed on cDNA using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd., Shanghai, China). Thermocycling conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and at 60°C for 30 sec. U6 was used for normalization in miRNA detection. The ΔΔCq method was used to quantify the relative expression levels of miR-214 (11). The primer sequences are listed in Table I.

Plasmid vector constructs. EcoRI and HindIII sites were inserted into the multiple cloning sites of the pcDNA6.2-GW/EmGFP vector (Invitrogen; Thermo Fisher Scientific, Inc.). The primary miR-214 sequence was amplified by PCR from genomic DNA, as aforementioned, and then cloned into the EcoRI and HindIII sites of the pcDNA6.2-GW/EmGFP vector. The wild-type (wt) and mutant (mut) Wnt3a 3’ untranslated region (UTR) sequences with SacI and XhoI restriction enzymes were synthesized by Sangon Biotech. Co., Ltd. (Shanghai, China) and cloned between the SacI and XhoI sites of pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega Corporation, Madison, WI, USA). The 3’UTR sequences are listed in Table I. Wnt3a was cloned into a GV230 vector (Shanghai GeneChem Co., Ltd., Shanghai, China).

Luciferase activity assay. Potential target genes for miR-214 were predicted using RegRNA online software version 2.0 (http://regrna2.mbc.nctu.edu.tw). A potential miR-214-binding site in the 3’-UTR of Wnt3a mRNA was identified. To determine whether Wnt3a was a direct target of miR-214, HepG2 cells were co-transfected with miR-214 and Wnt3a 3’UTR or mut Wnt3a 3’UTR pmirGLO plasmid, using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) as the transfection reagent, according to manufacturer's protocol. HepG2 cells co-transfected with miR-214 and pmirGLO vector were used as the control. After 48 h, luciferase activity was detected using the Dual-Luciferase Reporter Assay system (Promega Corporation) according to the manufacturer's protocol.

Cell proliferation assay. Cells were seeded into 96-well plates at a density of 5,000 cells/well. Cells were transfected with miR-214, miR-214 inhibitor, small interfering RNA(si)

Table I. Sequences of primers, inhibitors and UTRs used in the present study.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>U6</td>
<td>RT: CGCTTCAACGATTCTGCTGTCAT</td>
</tr>
<tr>
<td></td>
<td>Forward: GCTCCGGCAGACATATACTAA</td>
</tr>
<tr>
<td></td>
<td>Reverse: CGCTTCAGAATTTCGCTGTGTCAT</td>
</tr>
<tr>
<td>miR-214</td>
<td>RT: GTCTGATCCAGTGTCGTGGTTCGAG</td>
</tr>
<tr>
<td></td>
<td>AGTGGCGGAATTGCAGCATCGGATACGACA</td>
</tr>
<tr>
<td></td>
<td>CTGGCCT</td>
</tr>
<tr>
<td>miR-214-inhibitor</td>
<td>RT: TGCTACAGCAGGACAGACAGAC</td>
</tr>
<tr>
<td>miR-214-inhibitor-ctrl</td>
<td>ACTGCCGTCTGTGCTGCTGT</td>
</tr>
<tr>
<td>si-ctrl-S</td>
<td>CATGACTTTTTGTTAGTACAA</td>
</tr>
<tr>
<td>si-ctrl-AS</td>
<td>UUCUCGAACGUGUCAGCUGUT</td>
</tr>
<tr>
<td>siWnt3a-S</td>
<td>ACCGUGACGUGUCGAGAATT</td>
</tr>
<tr>
<td>siWnt3a-AS</td>
<td>CCCACUGGAAUCUUCUUATT</td>
</tr>
<tr>
<td>Wnt3a</td>
<td>UAAAGAGUAAUGCGUGGTT</td>
</tr>
<tr>
<td>3’UTR-WS</td>
<td>CCTGCCAGGGAATTGCCTGTGCC</td>
</tr>
<tr>
<td>Wnt3a</td>
<td>TCGAGGCGAGCCGGAGCTGTTCCCTGG</td>
</tr>
<tr>
<td>3’UTR-WA</td>
<td>CAGGGAGCT</td>
</tr>
<tr>
<td>Wnt3a</td>
<td>CCGTCCAGGGAACCTGGCCAGGCTG</td>
</tr>
<tr>
<td>3’UTR-MS</td>
<td>TCGAGGCGAGGTCGCTGCTGCTGCTG</td>
</tr>
<tr>
<td>Wnt3a</td>
<td>CAGGGAGCT</td>
</tr>
<tr>
<td>3’UTR-MA</td>
<td>RT, reverse transcriptase; miR, microRNA;</td>
</tr>
<tr>
<td></td>
<td>UTR, untranslated region; S, sense; AS,</td>
</tr>
<tr>
<td></td>
<td>antisense; WS, wild-type sense strand; WA,</td>
</tr>
<tr>
<td></td>
<td>wild-type antisense strand; MS, mutated</td>
</tr>
<tr>
<td></td>
<td>sense strand; MA, mutated antisense strand.</td>
</tr>
</tbody>
</table>

RT, reverse transcriptase; miR, microRNA; UTR, untranslated region; S, sense; AS, antisense; WS, wild-type sense strand; WA, wild-type antisense strand; MS, mutated sense strand; MA, mutated antisense strand.
Figure 1. miR-214 is downregulated in liver cancer and targets Wnt3a. (A) Reverse transcription-quantitative polymerase chain reaction was performed to examine the expression of miR-214 in 24 paired human hepatocellular carcinoma and non-tumor tissues. (B) Relative expression of miR-214 in liver cancer cell lines and a normal liver cell line. **P<0.01; *P<0.05. (C) miR-214 seed region sequence in the 3'UTR of Wnt3a. (D) Wnt3a protein expression as detected by immunohistochemistry. (E) miR-214 was co-transfected with pmirGLO, pmirGLO-Wnt3a-3'-UTR-wt or pmirGLO-Wnt3a-3'-UTR-mut in HepG2 cells. Relative luciferase activity was measured after 48 h. *P<0.05 vs. control. miR, microRNA; mut/M, mutant; UTR, untranslated region; wt/W, wild-type.
YANG et al.: miR-214 SUPPRESSES LIVER CANCER BY TARGETING Wnt3a.

miR-214 was transfected with Lipofectamine 2000 as the transfection reagent, according to the manufacturer’s protocol. The miR-214 inhibitor was synthesized by Sangon Biotech Co., Ltd. The siWnt3a and the corresponding control (ctrl) siRNA were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). Cell Counting kit-8 (CCK8; 7Sea Biotech, Shanghai, China) assay was performed according to the manufacturer’s protocol. Optical density at 450 nm was measured 24, 48, and 72 h post-transfection using the FLUOstar OPTIMA microplate reader (BMG Labtech GmbH, Ortenberg, Germany), in order to measure cell proliferation.

Figure 2. miR-214 inhibits the proliferation of liver cancer cells. CCK8 assay was performed to detect the effects of miR-214 on cell proliferation at 24, 48, and 72 h in (A) HepG2 and (B) Hep3B cells. CCK8 assay was performed to detect the effects of siWnt3a on cell proliferation at 24, 48 and 72 h in (C) HepG2 and (D) Hep3B cells. Wnt3a overexpression vector was co-transfected with miR-ctrl or miR-214 into (E) HepG2 and (F) Hep3B cells, and cell proliferation was detected by CCK8 assay. *P<0.05; **P<0.01 vs. miR-ctrl + Wnt3a-ctrl. CCK8, Cell Counting kit-8; ctrl, control; miR, microRNA; OD, optical density; si, small interfering RNA.

Wnt3a, or their respective controls using Lipofectamine 2000 as the transfection reagent, according to the manufacturer’s protocol. The miR-214 inhibitor was synthesized by Sangon Biotech Co., Ltd. The siWnt3a and the corresponding control (ctrl) siRNA were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). Cell Counting kit-8 (CCK8; 7Sea Biotech, Shanghai, China) assay was performed according to the manufacturer’s protocol. Optical density at 450 nm was measured 24, 48 and 72 h post-transfection using the FLUOstar OPTIMA microplate reader (BMG Labtech GmbH, Ortenberg, Germany), in order to measure cell proliferation.

Cell cycle analysis. HepG2 and Hep3B cells were transfected with miR-214, miR-control (ctrl), miR-214 inhibitor, inhibitor-ctrl, siWnt3a or si-ctrl (Shanghai GenePharma Co., Ltd.) using Lipofectamine 2000 according to the manufacturer’s instructions. At 48 h post-transfection, 1x10⁶ cells were harvested and washed in PBS, then fixed with 70% ice-cold ethanol at 4°C overnight. The cells were washed in PBS and then incubated at 4°C with 0.1 mg/ml RNase A and 0.05 mg/ml propidium iodide (PI; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 30 min. Fluorescence-activated cell sorting was performed using a BD FACS Sort flow cytometer (BD).
miR-214 is downregulated in liver cancer and targets Wnt3a. To explore the expression of miR-214 in liver cancer development, the expression levels of miR-214 were detected in 24 pairs of HCC and matched normal tissue samples using RT-qPCR. miR-214 was significantly downregulated in HCC tissue samples compared with in matched non-tumor tissues, as presented in Fig. 1A. In addition, miR-214 was downregulated in the examined liver cancer cells (SMMC-7721, Hep3B, HepG2) compared with in normal HL-7702 hepatocytes (Fig. 1B). These findings suggested that miR-214 was downregulated in HCC tissues and liver cancer cell lines; therefore, miR-214 may act as a potential anti-oncogenic miRNA in liver cancer.

The prediction of miR-214 targets was acquired using RegRNA. Wnt3a was identified as a potential target gene of miR-214. A miR-214 binding site was identified in the 3'UTR of Wnt3a (Fig. 1C). Immunohistochemistry demonstrated that Wnt3a protein expression was increased in HCC samples compared with in normal tissues (Fig. 1D). The protein expression levels of Wnt3a were also measured by western blotting in HepG2 cells transfected with miR-214 or miR-ctrl, and the results demonstrated that miR-214 overexpression was able to reduce Wnt3a protein expression (Fig. 1E). Dual-luciferase reporter assay was employed to determine whether Wnt3a was a direct target of miR-214. Luciferase activity was significantly reduced following co-transfection with miR-214 and wt Wnt3a 3'UTR compared with the control; however, luciferase activity was not altered following co-transfection with miR-214 and mut Wnt3a 3'UTR (Fig. 1F). These results provided direct evidence that Wnt3a was a target of miR-214.

miR-214 suppresses liver cancer cell growth via Wnt3a targeting. To explore the role of miR-214 in liver cancer cell growth, HepG2 and Hep3B cells were transfected with miR-214, miR-ctrl, siWnt3a or si-ctrl. Overexpression of miR-214 suppressed the growth of HepG2 and Hep3B cells following transfection for 24, 48 and 72 h compared with control vector-transfected cells (Fig. 2A and B). The results of Wnt3a silencing were consistent with those of miR-214 overexpression. Based on CCK8 assays (Fig. 2C and D), siWnt3A inhibited the growth of HepG2 and Hep3B cells. To further demonstrate that miR-214 suppressed the growth of HepG2 and Hep3B by targeting Wnt3a, Wnt3a overexpression vector and miR-ctrl or miR-214 were co-transfected into HepG2 and Hep3B cells. The results demonstrated that overexpression of Wnt3a can mitigate the growth inhibition caused by overexpression of miR-214 (Fig. 2E and F).

Overexpression of miR-214 and silencing of Wnt3a inhibits liver cancer cell proliferation via cell cycle regulation. HepG2 and Hep3B cells were transfected with miR-214 or miR-ctrl, and siWnt3a or si-ctrl. Cell cycle distribution, as detected by flow cytometry, revealed an accumulation of HepG2 and Hep3B cells in G0 phase in the miR-214 overexpression groups compared with the miR-ctrl groups (Fig. 3A and B). In addition, the number of cells in G0 phase was increased following transfection with siWnt3a compared with the control groups (Fig. 3C and D). These results suggested that overexpression of miR-214 or Wnt3a silencing may induce G0 cell cycle arrest.

Knockdown of miR-214 contributes to liver cancer cell proliferation. miR-214 inhibitor was used to further investigate the
YANG et al: miR-214 SUPPRESSES LIVER CANCER BY TARGETING Wnt3a

effects of miR-214 silencing on liver cancer cell proliferation. HepG2 and Hep3B cells were transfected with miR-214 inhibitor or inhibitor-ctrl, and the expression levels of miR-214 were detected (Fig. 4A and B). Cell viability was measured using the CCK8 assay; transfection with the miR-214 inhibitor increased the proliferation of HepG2 cells compared with the control group (Fig. 4C and D). The number of cells in G1 phase was reduced in the Hep3B cells transfected with miR-214 inhibitor compared with the control group (Fig. 4E and F).

Discussion

Previous studies have supported the role of miRNAs in tumorigenesis, including human liver cancer, and their functions as tumor suppressors or oncogenes (12,13). These small non-protein-coding RNAs are able to target numerous genes, including oncogenes, leading to the degradation of target mRNAs and inhibition of translation (14). miRNA dysregulation is associated with human cancer; specifically, miR-214 is a tumor suppressor of HCC (15). The present study revealed that miR-214 is downregulated in HCC cancer tissues and liver cancer cell lines, and may act as a tumor suppressor via Wnt3a signaling.

The Wnt/β-catenin signaling pathway is highly conserved and serves an essential role in regulating a series of genes associated with processes including embryonic development, stem cell maintenance and tissue homeostasis, and its disruption is a common cause of numerous types of cancer (16-18). In addition, the pathway is important during the development of HCC (19). Previous studies have demonstrated that β-catenin-activating mutations may associate with HCC, thus establishing an association between Wnt signaling and HCC (20,21) and providing novel insight into the complex network underlying HCC. Wnts act through distinct canonical and noncanonical pathways (22). The canonical Wnt/β-catenin signaling pathway is involved in the transition from cell proliferation to myogenic differentiation (23). β-catenin is a central regulator in the Wnt/β-catenin pathway (24,25) and is present in the plasma membrane, cytoplasm and nucleus. The interplay between the cell cycle and Wnt signaling is complex and requires further study (26,27). Wnt3a is a member of the Wnt family located on human chromosome 17 (17q21) and is an important molecule in the Wnt/β-catenin pathway that can active the canonical Wnt signaling pathway (28). The

Figure 3. Overexpression of miR-214 or Wnt3a silencing affects cell cycle progression. Cell cycle analysis of (A) HepG2 and (B) Hep3B cells following transfection with miR-214 or miR-ctrl for 48 h. Cell cycle analysis of (C) HepG2 and (D) Hep3B cells following transfection with siWnt3a or si-ctrl for 48 h. *P<0.05. ctrl, control; miR, microRNA; si, small interfering RNA.
overexpression of Wnt3a expression serves an important role in hepatocarcinogenesis (29).

In conclusion, the present study demonstrated that Wnt3a is a target gene of miR-214. In addition, the results indicated that miR-214 may inhibit cell proliferation in liver cancer cells via Wnt3a targeting. These data provide experimental evidence to suggest that miR-214 acts as a tumor suppressor by suppressing the Wnt/β-catenin signaling pathway. Therefore, miR-214 may be considered a potential molecular therapeutic target for the treatment of liver cancer.

Acknowledgements
The present study was supported by the Scientific Research and Sharing Platform Construction Project of Shaanxi Province (grant no. 2015FWPT-14) and Research Support
Project of New Teacher of Xi’an Jiaotong University (grant no. YX1K078).

References


